111 Capital’s Relay Therapeutics RLAY Stock Holding History

111 Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24,911	Closed	-$86.2K	–	656
2025 Q2	$86.2K	Buy	+24,911	New	+$74.1K	0.01%	483

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

111 Capital's RLAY Position: Q3 2025 in Review

111 Capital sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 24,911 shares — an estimated $86.2K sold.

111 Capital first reported a position in RLAY in Q2 2025 and held it in 1 quarter. The position peaked at $86.2K in Q2 2025. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

111 Capital reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
111 Capital sold 24,911 Relay Therapeutics shares in Q3 2025, an estimated $86.2K.
111 Capital first reported a position in Relay Therapeutics in Q2 2025 and held it in 1 quarter.
111 Capital's Relay Therapeutics position peaked at $86.2K in Q2 2025.
199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.